Navigation Links
The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer
Date:10/5/2011

LAUSANNE, Switzerland, October 5, 2011 /PRNewswire/ --

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group with a focus on drug development and companion diagnostics, today presented the 'JCA-Mauvernay Award' to Doctor Hirofumi Arakawa from the National Cancer Center Research Institute in Tokyo, for his basic research on the 'identification and characterization of p53 target genes' and to Doctor Mineo Kurokawa from the University of Tokyo, for his applied research on 'the molecular pathogenesis and therapeutic targets of hematological malignancies'. The ceremony was held during the 70th Annual Meeting of the Japanese Cancer Association (JCA) in Nagoya, Japan. This year the theme was 'Forward Strides for Cancer Research - Grounds for a Confident Future'. Professor Tetsuo Noda, President of the JCA and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group™ presented both scientists with the 2011 Award for their outstanding and innovative research.

Dr Hirofumi Arakawa works in the division of Cancer Biology at the National Cancer Center Research Institute. Since 1999, he has focused on the p53 (protein 53) tumour suppressor, which functions mainly by controlling the expression of a battery of genes involved in life and death of the cell, and which is referred to as "the guardian of the genome". Dr. Arakawa has identified, characterised and reported over 20 p53-regulated target genes.

Recently his group discovered an unusual mechanism for mitochondrial quality control, in which the p53 pathway controls mitochondrial quality by repairing or eliminating unhealthy mitochondria, suggesting that cancer cells might accumulate unhealthy mitochondria due to p53 mutations. Maintenance of healthy mitochondria prevents aging, cancer, and a variety of degenerative diseases, therefore Dr Arakawa's research offers a new approach of cancer and mitochondrial quality control, suggesting that p53 is also a guardian of mitochondria.

Dr Mineo Kurokawa works in the department of Hematology and Oncology at the Graduate School of Medicine. For 20 years, he has studied the mechanisms of malignant transformation of hematopoietic stem cells (multipotent stem cells that give rise to all blood lineages) in order to elucidate the pathogenesis of blood malignancies. He focused on the role of transcription factors associated with human leukaemia. For instance he revealed the transforming activity of EVI1, a protein frequently activated in human leukaemia and elucidated its' functions that are involved in the prevention of cell death.

Through his pursuit of the pathogenetic significance of deregulated transcription factors in leukaemia, Dr Kurokawa has consistently contributed to the understanding of a mechanistic basis of leukaemia development and the identification of novel therapeutic targets of human haematological malignancies.

"We are proud to reward these very talented and inspiring scientists for their hard work and accomplishments. The jury's decision to nominate them was unanimous," said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™. "We wish them a lot of luck for the future hoping their work will lead to major medical developments eventually benefiting the patients in the years to come."

About Debiopharm Group™

Debiopharm Group™ (Debiopharm) is a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs. The group in-licenses, develops and/or co-develops promising biological and small molecule drug candidates having reached clinical development phases I, II or III, as well as earlier stage candidates. It develops its products for global registration and maximum commercial potential. The products are out-licensed to pharmaceutical partners for sales and marketing. Debiopharm is also active in the field of companion diagnostics with a view to progressing in the area of personalised medicine. Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

For more information on Debiopharm Group™, please visit: http://www.debiopharm.com.

Debiopharm S.A. Contact
Maurice Wagner
Director Corporate Affairs & Communication
Tel.: +41(0)21-321-01-11
Fax: +41(0)21-321-01-69
mwagner@debiopharm.com

Additional Media Contacts
In London
Maitland
Brian Hudspith
Tel: +44(0)20-7379-5151
bhudspith@maitland.co.uk

In New York
Russo Partners, LLC
Martina Schwarzkopf, Ph.D.
Account Executive
Tel: +1-212-845-4292
Fax: +1-212-845-4260
martina.schwarzkopf@russopartnersllc.com



'/>"/>
SOURCE The Debiopharm Group
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Circassia Acquires North American and Japanese Rights to Dopexamine
2. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
3. Japanese Cancer Association and Debiopharm Honour Japanese Research
4. Australian Authorities (TGA) First to Grant Final Product Approval for Intercells Vaccine to Prevent Japanese Encephalitis
5. GenVault Opens Japanese Subsidiary to Better Address Global Biobanking Market Growth
6. Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System
7. Forward-Thinking Patient Recruitment Company Poised to Create Bridges Between Japanese Clinical R&D Industry and Global Clinical Trial Marketplace
8. Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis
9. Intercell to Host Conference Call and Webcast Today on FDA Approval of IXIARO(R) Japanese Encephalitis Vaccine
10. Intercell Announces European Approval of New Vaccine, IXIARO(R), to Prevent Japanese Encephalitis
11. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... ... April 26, 2016 , ... BaseHealth ... has joined the company as Chief Business Officer. Arianpour, a genomics pioneer and ... to market, was most recently Chief Commercial Officer of Pathway Genomics. He has ...
(Date:4/26/2016)... ... April 26, 2016 , ... Mr. Palmer created the RPO business for ... multi-million dollar, multi-year managed services contract in the U.S. intelligence community with The SI ... team,” said John Younger, founder of Accolo. “We are growing and his experience ...
(Date:4/26/2016)... (PRWEB) , ... April 26, 2016 , ... ... announced receipt of a significant operating grant from 1Plus12 Corporation. The grant will ... commence pre-proposal activities as outlined on the organization's website http://www.ivsci.org , ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016  A new ... make more accurate underwriting decisions in a fraction ... timely, competitively priced and high-value life insurance policies ... screenings. With Force Diagnostics, rapid testing ... lifestyle data readings (blood pressure, weight, pulse, BMI, ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
Breaking Biology News(10 mins):